Clinical Trial Update: Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder [Phase 1, Phase 2]

View source ↗

Summary

Completed Phase 1/2 trial evaluating antithymocyte globulin in combination with chemotherapy to reduce graft-versus-host disease after donor stem cell transplan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms

Drugs mentioned

• Antithymocyte Globulin (anti-thymocyte globulin)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease | Phase 1, Phase 2 | Status: COMPLETED